Abstract
HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 26, No. 3In Response: Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessLetterPDF/EPUBIn Response: David Feinbloom and Kenneth A. Bauer David FeinbloomDavid Feinbloom Beth Israel Deaconess Medical Center, and VA Boston Healthcare System, Boston, Mass Search for more papers by this author and Kenneth A. BauerKenneth A. Bauer Beth Israel Deaconess Medical Center, and VA Boston Healthcare System, Boston, Mass Search for more papers by this author Originally published1 Mar 2006https://doi.org/10.1161/01.ATV.0000204348.87254.ccArteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:e29We appreciate the comments of Boos and Lip regarding the role of other hemostatic factors in predicting arterial thrombotic events. Because of limitations in the length of our article,1 we had to be selective in the topics that we covered and chose not to focus on markers of coagulation activation or endothelial cell damage. The former include prothrombin fragment F1+2, thrombin–antithrombin complex, as well as D-dimer, while the latter include plasma von Willebrand factor (vWF) levels and soluble E-selectin. We agree that there are considerable data supporting vWF as a marker of endothelial injury as well as prospective data demonstrating that elevated vWF is associated with an increased risk for myocardial infarction after adjustment for inflammatory effects.2In our review of hemostatic risk factors in predicting arterial thrombotic events, we primarily selected hemostatic factors that were measured in subjects at baseline rather than during an acute ischemic event. With respect to CD146-bearing circulating endothelial cells (CECs), the observations of Lee et al3 that concentrations of these cells rise in the setting of an acute coronary syndrome (ACS) and correlate with vWF are intriguing. Although statistically significant, we note that the adjusted odds ratios for elevated CECs 48 hours after clinical presentation with an ACS and major adverse cardiac outcomes at 30 days and 1 year are modest at 1.04 and 1.06, respectively.1 Feinbloom D, Bauer K. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005; 25: 2043–2053.LinkGoogle Scholar2 Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I, on behalf of the PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: The prospective epidemiological study of myocardial infarction (PRIME) study. Circulation. 2004; 109: 1343–1348.LinkGoogle Scholar3 Lee KW, Lip GYH, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin (IL)-6, and prognosis in patients with acute coronary syndromes. Blood. 2005; 105: 526–532.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails March 2006Vol 26, Issue 3Article InformationMetrics https://doi.org/10.1161/01.ATV.0000204348.87254.ccPMID: 16484603 Originally publishedMarch 1, 2006 PDF download Advertisement
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Arteriosclerosis, Thrombosis, and Vascular Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
